Alpha Tau Announces Participation in Upcoming Small-Cap Conference

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company") DRTS, a pioneer in alpha radiation cancer treatment, has made an official announcement confirming its participation in the forthcoming Sidoti Small-Cap Virtual Conference. This conference is renowned for showcasing small-cap companies to potential investors, offering a platform for business leaders to present their company strategies and growth potential. Alpha Tau's management team is set to take the stage to introduce their groundbreaking cancer therapy, Alpha DaRT™, to a broader audience.

Revolutionizing Cancer Treatment

Alpha Tau Medical Ltd., headquartered in the historical city of Jerusalem, Israel, stands at the forefront of medical innovation with its clinical-stage oncology therapy. By harnessing the power of alpha-emitting radiation, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is changing the landscape for treating solid cancers both within Israel and internationally. This proprietary technology offers new hope by targeting and destroying cancer cells with precision, minimizing damage to surrounding healthy tissue.

Market Potential of Alpha DaRT™

Alpha Tau's market presence, particularly with the stock ticker DRTS listed on NASDAQ, is a testament to their growing influence in the oncology sector. Through extensive research and development, commercialization of their therapy has the potential to impact countless lives, positioning Alpha Tau as a visionary in cancer treatment methodologies. The company's participation in the Sidoti Small-Cap Virtual Conference marks an important opportunity for investors to gauge the potential of Alpha Tau and the far-reaching implications of their work.

The Future of Alpha Tau

With an unwavering commitment to improving oncology treatments, Alpha Tau continues to invest in the progress of Alpha DaRT™. Showcasing their work to a diverse group of investors at the Sidoti Small-Cap Conference is a strategic move to foster partnerships, secure funding, and drive forward their mission to transform cancer therapy. For those tracking DRTS or looking to diversify their portfolio with innovative healthcare solutions, Alpha Tau's presentation at the conference is an event to watch.

AlphaTau, Cancer, Conference